Richard Carl Gregory

US Patent:

6358507, Mar 19, 2002

Filed:

Oct 12, 1999

Appl. No.:

09/416673

Inventors:

Johanne Kaplan - Sherborn MA
Donna Armentano - Belmont MA
Richard J. Gregory - Westford MA

Assignee:

Genzyme Corporation - Framingham MA

International Classification:

A61K 4800

US Classification:

424 932, 424 936, 4353201, 435 691, 435455, 435456, 435325, 435366, 435 911, 435 914, 435 9141, 435 9142, 435371

Abstract:

The present invention relates to transgene expression systems, related compositions comprising the transgene expression systems, and methods of making and using them. Preferred systems employ an adenovirus transgene expression vector comprising DNA encoding a transgene which codes for a desired product operably linked to expression control sequence, and at least a portion of the adenovirus E3 region and certain portions of the E4 region. The E4 portions comprise the open reading frame sequence known as E40RF3 and at least one other portion of E4. Preferably the E4 portion of the vector (or âE4 cassetteâ) includes E40RF3 and at least one other portion selected from E40RF4, E40RF6/7 and E40RF3/4. The invention has a number of important features including improving persistency of transgene expression in a desired host cell. The transgene expression systems of the present invention are useful for a variety of applications including providing persistent cellular expression of the transgene in vitro and in vivo.

US Patent:

6432927, Aug 13, 2002

Filed:

May 26, 2000

Appl. No.:

09/579897

Inventors:

Richard J. Gregory - Westford MA
Karen Vincent - Arlington MA

Assignee:

Genzyme Corporation - Cambridge MA

International Classification:

A61K 3170

US Classification:

514 44, 4353201, 435325, 435 914, 435455, 536 234, 536 241, 424 932

Abstract:

The present invention provides recombinant nucleic acid molecules encoding a chimeric transactivator protein including a DNA binding domain of a DNA binding protein and a protein domain capable of transcriptional activation. The present invention also provides recombinant viral and non-viral vectors that are able to infect and/or transfect and sustain expression of a biologically active chimeric transactivator proteins in mammalian cells. Also provided are host cell lines and non-human transgenic animals capable of expressing biologically active chimeric transactivator proteins. In another aspect, compositions and methods for treating or preventing ischemic damage associated with hypoxia-related disorders are provided.

US Patent:

6485720, Nov 26, 2002

Filed:

Aug 8, 2001

Appl. No.:

09/924925

Inventors:

Johanne Kaplan - Sherborn MA
Donna Armentano - Belmont MA
Richard J. Gregory - Westford MA

Assignee:

Genzyme Corporation - Cambridge MA

International Classification:

A61K 4800

US Classification:

424 932, 424 931, 424 936, 4353201, 435455, 435456, 435457, 435 691, 435325, 435366

Abstract:

The present invention relates to transgene expression systems, related compositions comprising the transgene expression systems, and methods of making and using them. Preferred systems employ an adenovirus transgene expression vector comprising DNA encoding a transgene which codes for a desired product operably linked to expression control sequence, and at least a portion of the adenovirus E3 region and certain portions of the E4 region. The E4 portions comprise the open reading frame sequence known as E4ORF3 and at least one other portion of E4. Preferably the E4 portion of the vector (or âE4 cassetteâ) includes E4ORF3 and at least one other portion selected from E4ORF4, E4ORF6/7 and E4ORF3/4. The invention has a number of important features including improving persistency of transgene expression in a desired host cell. The transgene expression systems of the present invention are useful for a variety of applications including providing persistent cellular expression of the transgene in vitro and in vivo.

US Patent:

7053062, May 30, 2006

Filed:

Jul 3, 2002

Appl. No.:

10/190394

Inventors:

Richard J. Gregory - Westford MA, US
Karen Vincent - Arlington MA, US

Assignee:

Genzyme Corporation - Cambridge MA

International Classification:

A61K 31/70
C12N 15/00
C12N 15/63
C07H 21/04

US Classification:

514 44, 4353201, 435455, 536 234

Abstract:

The present invention provides recombinant nucleic acid molecules encoding a chimeric transactivator protein including a DNA binding domain of a DNA binding protein and a protein domain capable of transcriptional activation. The present invention also provides recombinant viral and non-viral vectors that are able to infect and/or transfect and sustain expression of a biologically active chimeric transactivator proteins in mammalian cells. Also provided are host cell lines and non-human transgenic animals capable of expressing biologically active chimeric transactivator proteins. In another aspect, compositions and methods for treating or preventing ischemic damage associated with hypoxia-related disorders are provided.

US Patent:

7118911, Oct 10, 2006

Filed:

Jul 2, 1993

Appl. No.:

08/087132

Inventors:

Richard Gregory - Ayer MA, US
Seng H. Cheng - Boston MA, US
Alan Smith - Wellesley MA, US
Sucharita Paul - Grafton MA, US
Kathleen M. Hehir - Grafton MA, US
John Marshall - Milford MA, US

Assignee:

Genzyme Corporation - Cambridge MA

International Classification:

C12N 15/00
C07H 21/00

US Classification:

4353201, 536 231

Abstract:

Disclosed are full length isolated DNAs encoding cystic fibrosis transmembrane conductance regulator (CFTR) protein and a variety of mutants thereof. Also disclosed are antibodies specific for various CFTR domains and methods for their production. Expression of CFTR from cells transformed with these CFTR genes or cDNAs demonstrate surprising CFTR intracellular distributions and results thereby providing for new diagnostic and therapeutic procedures.

US Patent:

7318919, Jan 15, 2008

Filed:

Jun 3, 2002

Appl. No.:

10/161539

Inventors:

Richard Gregory - Westford MA, US
Donna Armentano - Belmont MA, US
Larry A. Couture - Louisville CO, US
Alan E. Smith - Dover MA, US

Assignee:

Genzyme Corporation - Cambridge MA

International Classification:

A61K 48/00
C12N 15/861

US Classification:

424 932, 4353201, 435455, 435456

Abstract:

Gene Therapy vectors, which are especially useful for cystic fibrosis, and methods for using the vectors are disclosed.

US Patent:

8283331, Oct 9, 2012

Filed:

Oct 8, 2008

Appl. No.:

12/682149

Inventors:

Richard I Gregory - Brookline MA, US
George Q Daley - Weston MA, US
Srinivas R Viswanathan - Brookline MA, US

Assignee:

Children's Medical Center Corporation - Boston MA

International Classification:

C12N 15/11

US Classification:

514 44A

Abstract:

The present invention relates generally to methods to regulate microRNA (miRNA) biogenesis, in particular the regulation of the processing of pri-miRNA to mature miRNA by Lin-28 and/or variants such as Lin28B. In particular, the present invention relates to methods and compositions comprising at least one agent which inhibits Lin-28 function or activity and/or expression to increase the processing of pri-mRNA to mature miRNA. More specifically, one aspect of the invention is directed to treating and/or preventing cancer in a subject by administering an agent that inhibits Lin-28 activity or expression to a subject, preferably a human subject.

US Patent:

20020137212, Sep 26, 2002

Filed:

May 18, 2001

Appl. No.:

09/860211

Inventors:

Richard Gregory - Westford MA, US
Ken Wills - San Diego CA, US
Daniel Maneval - Carlsbad CA, US

Assignee:

Canji,Inc. - San Diego CA

International Classification:

C12N015/861
C12N007/01

US Classification:

435/456000, 435/235100, 435/320100

Abstract:

This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).